Drug Profile
Humanised anti-CD19 chimeric antigen receptor T cell therapy - Kite Pharma
Alternative Names: Fully human anti-CD19 CAR - Kite Pharma; HuCAR-19 T-cell therapy; Second generation human anti-CD19 chimeric antigen receptor T cell therapy - Kite PharmaLatest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Haematological-malignancies(Late-stage disease) in USA (Parenteral, Infusion)
- 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences